Autolus Historical Income Statement
| AUTL Stock | USD 2.98 0.04 1.36% |
Historical analysis of Autolus Therapeutics income statement accounts such as Selling General Administrative of 25.9 M, Total Revenue of 2 M or Other Operating Expenses of 107.1 M can show how well Autolus Therapeutics performed in making a profits. Evaluating Autolus Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Autolus Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Autolus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Autolus Therapeutics is a good buy for the upcoming year.
Autolus |
About Autolus Income Statement Analysis
Autolus Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Autolus Therapeutics shareholders. The income statement also shows Autolus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Autolus Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Autolus Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Autolus Therapeutics. It is also known as Autolus Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Autolus Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Autolus Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.At this time, Autolus Therapeutics' Interest Expense is quite stable compared to the past year. Total Revenue is expected to rise to about 2 M this year, although the value of Gross Profit will most likely fall to (5.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 8.5M | 7.4M | 6.6M | 4.5M | Interest Income | 262K | 1.7M | 11.9M | 12.5M |
Autolus Therapeutics income statement Correlations
Click cells to compare fundamentals
Autolus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Autolus Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.1M | 1.9M | 1.1M | 8.9M | 45.1M | 47.3M | |
| Selling General Administrative | 39.5M | 35.0M | 31.9M | 31.9M | 45.6M | 25.9M | |
| Total Revenue | 2.9M | 242K | 2.3M | 6.2M | 1.7M | 2.0M | |
| Gross Profit | (1.7M) | (134.6M) | (126.3M) | (131.0M) | (4.9M) | (5.1M) | |
| Other Operating Expenses | 144.9M | 168.4M | 166.7M | 173.7M | 196.7M | 107.1M | |
| Operating Income | (137.9M) | (168.1M) | (164.2M) | (163.8M) | (195.0M) | (185.3M) | |
| Net Income From Continuing Ops | (123.8M) | (142.1M) | (142.1M) | (148.8M) | (158.2M) | (150.3M) | |
| Ebit | (137.9M) | (166.3M) | (140.6M) | (143.0M) | (163.3M) | (155.2M) | |
| Research Development | 105.4M | 134.9M | 134.8M | 142.0M | 150.0M | 81.9M | |
| Cost Of Revenue | 4.6M | 134.9M | 128.7M | 137.2M | 6.6M | 6.2M | |
| Total Operating Expenses | 144.9M | 168.4M | 166.7M | 173.7M | 196.7M | 107.7M | |
| Income Before Tax | (139.0M) | (166.3M) | (166.0M) | (173.2M) | (208.4M) | (198.0M) | |
| Total Other Income Expense Net | (1.1M) | 1.9M | 109.2M | (9.4M) | (13.4M) | (12.7M) | |
| Net Income Applicable To Common Shares | (123.8M) | (142.1M) | (142.1M) | (148.8M) | (134.0M) | (127.3M) | |
| Net Income | (123.8M) | (142.1M) | (142.1M) | (148.8M) | (208.4M) | (198.0M) | |
| Income Tax Expense | (15.2M) | (24.2M) | (23.9M) | (24.4M) | (19K) | (20.0K) | |
| Tax Provision | (15.2M) | (24.2M) | (23.9M) | (24.4M) | (17.5M) | (18.4M) | |
| Interest Income | 2.5M | 536K | 262K | 1.7M | 11.9M | 12.5M | |
| Depreciation And Amortization | 4.6M | 5.7M | 8.5M | 7.4M | 6.6M | 4.5M | |
| Ebitda | (133.2M) | (160.5M) | (132.0M) | (135.5M) | (156.8M) | (148.9M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.